HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Plasma globotriaosylsphingosine as a biomarker of Fabry disease.

Abstract
Fabry disease is an X-linked genetic disorder caused by a deficiency of alpha-galactosidase A (GLA) activity. As enzyme replacement therapy (ERT) involving recombinant GLAs has been introduced for this disease, a useful biomarker for diagnosis and monitoring of therapy has been strongly required. We measured globotriaosylsphingosine (lyso-Gb3) and globotriaosylceramide (Gb3) in plasma samples from ten hemizygous males (six classic and four variant cases) and eight heterozygous females with Fabry disease, and investigated the responses of plasma lyso-Gb3 and Gb3 in a male Fabry patient who had undergone ERT for 4years to determine whether plasma lyso-Gb3 and Gb3 could be biomarkers of Fabry disease. The results revealed that plasma lyso-Gb3 was apparently increased in male patients and was higher in cases of the classic form than those of the variant one. In Fabry females, plasma lyso-Gb3 was moderately increased in both symptomatic and asymptomatic cases, and there was a correlation between the increase in lyso-Gb3 and the decrease in GLA activity. As to plasma Gb3, the levels in the variant Fabry hemizygotes and Fabry heterozygotes could not be distinguished from those in the controls, although those in the classic Fabry hemizygotes were increased. The plasma lyso-Gb3 level in the Fabry patient who had received ERT was elevated at the baseline and fell more dramatically on ERT than that of Gb3. Plasma lyso-Gb3 could thus be a potential biomarker of Fabry disease.
AuthorsTadayasu Togawa, Takashi Kodama, Toshihiro Suzuki, Kanako Sugawara, Takahiro Tsukimura, Toya Ohashi, Nobuyuki Ishige, Ken Suzuki, Teruo Kitagawa, Hitoshi Sakuraba
JournalMolecular genetics and metabolism (Mol Genet Metab) Vol. 100 Issue 3 Pg. 257-61 (Jul 2010) ISSN: 1096-7206 [Electronic] United States
PMID20409739 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2010 Elsevier Inc. All rights reserved.
Chemical References
  • Biomarkers
  • Glycolipids
  • Recombinant Proteins
  • Sphingolipids
  • Trihexosylceramides
  • globotriaosyl lysosphingolipid
  • globotriaosylceramide
  • alpha-Galactosidase
Topics
  • Adolescent
  • Adult
  • Aged
  • Biomarkers (blood)
  • Case-Control Studies
  • Fabry Disease (blood, drug therapy, genetics)
  • Female
  • Glycolipids (blood)
  • Heterozygote
  • Humans
  • Male
  • Middle Aged
  • Recombinant Proteins (therapeutic use)
  • Sphingolipids (blood)
  • Trihexosylceramides (blood)
  • Young Adult
  • alpha-Galactosidase (blood, genetics, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: